Photocure (LSE:0IMT) - Prezzo delle azioni, notizie e analisi

0IMT Panoramica delle azioni

0IMT analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	4/6
Prestazioni passate	3/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Negoziato a 87% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 94.94% all'anno

È diventato redditizio quest'anno

Analisi del rischio

Non sono stati rilevati rischi per 0IMT dai nostri controlli di rischio.

Photocure ASA Concorrenti

Animalcare Group

AIM:ANCR

UK£148.5m

ECO Animal Health Group

AIM:EAH

UK£43.4m

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

hVIVO

AIM:HVO

UK£136.1m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Photocure
Prezzi storici delle azioni
Prezzo attuale dell'azione	NOK 51.50
Massimo di 52 settimane	NOK 71.90
Minimo di 52 settimane	NOK 48.05
Beta	0.99
1Variazione di 1 mese	-2.83%
Variazione a 3 mesi	3.00%
Variazione di 1 anno	2.80%
3Variazione a 3 anni	-46.52%
Variazione a 5 anni	-40.22%
Variazione dall'IPO	13.19%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	0IMT	GB Pharmaceuticals	GB Mercato
7D	-1.5%	5.0%	2.2%
1Y	2.8%	2.5%	8.8%

Ritorno vs Industria: 0IMT ha trovato corrispondenza nel UK Pharmaceuticals che ha restituito 2.5 % nell'ultimo anno.

Rendimento vs Mercato: 0IMT ha avuto una performance inferiore al mercato UK che ha registrato un rendimento 8.8 % nell'ultimo anno.

Volatilità dei prezzi

Is 0IMT's price volatile compared to industry and market?
0IMT volatility
0IMT Average Weekly Movement	4.9%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Prezzo delle azioni stabile: 0IMT non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 5% ) di 0IMT è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1993	102	Dan Schneider	www.photocure.com

Photocure ASA, insieme alle sue controllate, si occupa di ricerca, sviluppo, produzione, distribuzione, commercializzazione e vendita di prodotti farmaceutici nei Paesi nordici, in Germania, Francia, Austria, Regno Unito, BeNeLux, Italia, altri Paesi europei, Canada e Stati Uniti. Opera attraverso i segmenti Commercial Franchise e Development Portfolio. L'azienda offre Hexvix/Cysview per il rilevamento e la gestione del tumore alla vescica.

Photocure ASA Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Photocure con la sua capitalizzazione di mercato?
0IMT statistiche fondamentali
Capitalizzazione di mercato	NOK 1.31b
Guadagni(TTM)	NOK 14.16m
Ricavi(TTM)	NOK 526.25m

92.6x

Rapporto P/E

2.5x

Rapporto P/S

0IMT è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
0IMT Conto economico (TTM)
Ricavi	NOK 526.25m
Costo del fatturato	NOK 29.11m
Profitto lordo	NOK 497.15m
Altre spese	NOK 482.98m
Guadagni	NOK 14.16m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.52
Margine lordo	94.47%
Margine di profitto netto	2.69%
Rapporto debito/patrimonio netto	0%

Come si è comportato 0IMT nel lungo periodo?

Vedi performance storica e confronto

0IMT Panoramica delle azioni

Premi

Analisi del rischio

Photocure ASA Concorrenti

AIM:ANCR

UK£148.5m

AIM:EAH

UK£43.4m

LSE:HIK

UK£4.4b

AIM:HVO

UK£136.1m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

New minor risk - Share price stability

Photocure ASA Announces Board Appointments

First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023)

Photocure ASA Reiterates Financial Guidance for the Year 2024

Recent updates

Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

New minor risk - Share price stability

Photocure ASA Announces Board Appointments

First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023)

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Full year 2023 earnings released: EPS: kr0.01 (vs kr2.66 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022)

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Second quarter 2023 earnings released: EPS: kr0.16 (vs kr0.68 loss in 2Q 2022)

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Insufficient new directors

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

First quarter 2022 earnings released: kr0.82 loss per share (vs kr0.57 profit in 1Q 2021)

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) announces an Equity Buyback for 2,682,006 shares, representing 10% of its issued share capital.

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda